All In Biotech

Drug Trial Radar · NCT05718895

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

An Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Mar 27, 2023

Primary completion

Dec 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Antengene Biologics LimitedIndustry
Sponsor type
Industry
First posted
Feb 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

  • ATG-022Drug

    Dose Escalation Phase: A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of "3+3" design.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: Up to 21 Days
  2. MTDTime frame: Up to 21 Days
  3. RP2DTime frame: Up to 21 Days

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Cancer Research SA Pty Ltd

    Adelaide, Australia · Completed

  • Cabrini Health Limited

    Malvern, Australia · Recruiting

  • Integrated Clinical Oncology Network Pty Ltd (Icon)

    South Brisbane, Australia · Recruiting

  • Beijing GoBroad Hospital

    Beijing, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • Anhui Provincial Hospital

    Hefei, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China · Recruiting

  • Jinan Central Hospital

    Jinan, China · Recruiting

  • Gansu provincial cancer hospital [recruiting]

    Lanzhou, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

  • Tongren Hospital Shanghai

    Shanghai, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, China · Recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiangzhuang, China · Recruiting

  • Shanxi provincial cancer hospital

    Taiyuan, China · Recruiting

  • Tianjin Medical Universuty Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, China · Recruiting

  • The First affiliated hospital of Xi'An Jiao Tong Ubiversity

    Xi'an, China · Recruiting

  • Xuzhou Central Hospital

    Xuzhou, China · Recruiting

  • General Hospital of Ningxia Medical University

    Yinchuan, China · Recruiting

  • The First Affiliated Hospital of Zhenghzou University

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.